Innovent Biomedical Technology

Innovent Biologics is a leading biopharmaceutical company based in China dedicated to developing, manufacturing, and commercializing high-quality innovative medicines for the treatment of oncology, metabolic, autoimmune, and ophthalmology diseases. Founded in 2011, the company has established a fully integrated platform encompassing R&D, CMC, and commercialization. Its flagship product, Tyvyt (sintilimab), is a PD-1 inhibitor that has gained significant market share in China and is part of a major global collaboration with Eli Lilly. Innovent maintains a robust pipeline of over 30 clinical programs and operates one of the largest biologics manufacturing facilities in China that meets international GMP standards.